CVA
MCID: CRB039
MIFTS: 71

Cerebrovascular Disease (CVA)

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Cerebrovascular Disease

MalaCards integrated aliases for Cerebrovascular Disease:

Name: Cerebrovascular Disease 12 55 15
Cerebrovascular Disorders 44 72
Cerebrovascular Accident 12 72
Cerebrovascular Disorder 12 17
Stroke 12 44
Cva 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6713
NCIt 50 C2938 C3390
SNOMED-CT 68 62914000 82797006
UMLS 72 C0007820 C0038454

Summaries for Cerebrovascular Disease

Disease Ontology : 12 An vascular disease that is characterized by dysfunction of the blood vessels supplying the brain.

MalaCards based summary : Cerebrovascular Disease, also known as cerebrovascular disorders, is related to retinal vascular occlusion and peripheral artery disease, and has symptoms including seizures, tremor and angina pectoris. An important gene associated with Cerebrovascular Disease is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Metabolism of water-soluble vitamins and cofactors. The drugs Ticlopidine and Glyburide have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Wikipedia : 75 Cerebrovascular disease includes a variety of medical conditions that affect the blood vessels of the... more...

Related Diseases for Cerebrovascular Disease

Diseases related to Cerebrovascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2153)
# Related Disease Score Top Affiliating Genes
1 retinal vascular occlusion 33.3 SELP MTHFR F2
2 peripheral artery disease 33.3 SELP CRP APOB ACE
3 spinal cord infarction 33.1 MTHFR F2
4 grange syndrome 33.0 SELP PLAT MTHFR
5 vascular dementia 32.7 SERPINA3 PON1 NOTCH3 MTHFR APP APOE
6 stroke, ischemic 32.6 SELP PON1 PLAT NOTCH3 MTHFR F2
7 cerebral atherosclerosis 32.4 MTHFR APOE APOA1 ACE
8 cerebral amyloid angiopathy, cst3-related 32.4 SERPINA3 APP APOE
9 carotid stenosis 32.1 SELP MTHFR CRP APOE ACE
10 intracranial embolism 32.0 PLAT F2
11 dementia 31.9 NOTCH3 APP APOE ACHE
12 thrombophilia due to thrombin defect 31.7 PLAT MTHFR F2
13 sleep apnea 31.7 CRP APOE ACE
14 homocysteinemia 31.6 MTR MTHFR F2 CRP
15 angina pectoris 31.6 PLAT CRP ACE
16 endocarditis 31.5 PLAT F2 CRP
17 hyperlipoproteinemia, type iii 31.5 APOE APOB APOA1
18 migraine with aura 31.4 NOTCH3 MTHFR ACE
19 atherosclerosis susceptibility 31.4 PON1 CRP APOE APOB APOA1
20 retinal artery occlusion 31.3 MTHFR F2 ACE
21 lipid metabolism disorder 31.3 CRP APOE APOB APOA1 ACE
22 patent foramen ovale 31.3 PLAT MTHFR F2
23 carotid artery disease 31.3 CRP APOE APOB APOA1 ACE
24 platelet aggregation, spontaneous 31.2 SERPINA3 SELP PLAT
25 thrombosis 31.2 SELP PLAT MTHFR F2
26 porencephaly 31.2 MTHFR F2 COL4A1
27 ischemia 31.2 SELP PON1 PLAT APP ACE
28 intermediate coronary syndrome 31.2 SELP PLAT CRP ACE
29 binswanger's disease 31.2 NOTCH3 APP APOE ACHE
30 pulmonary embolism 31.1 PLAT MTHFR F2 CRP
31 thrombocytosis 31.0 SELP F2 CRP
32 hypertriglyceridemia, familial 31.0 APOE APOB APOA1
33 peripheral vascular disease 31.0 SELP PLAT F2 CRP APOB APOA1
34 antiphospholipid syndrome 31.0 SELP PLAT MTHFR F2
35 arteriosclerosis 31.0 SELP PON1 CRP APOE APOB APOA1
36 aortic atherosclerosis 31.0 PON1 APOE ACE
37 vascular disease 31.0 SELP PON1 PLAT MTR MTHFR F2
38 pulmonary edema 30.9 F2 CRP ACE
39 thrombophilia due to activated protein c resistance 30.9 PLAT MTHFR F2
40 intermittent claudication 30.9 SELP F2 CRP ACE
41 hemorrhage, intracerebral 30.9 PLAT COL4A1 APP APOE ACE
42 homocystinuria due to deficiency of n -methylenetetrahydrofolate reductase activity 30.9 MTR MTHFR
43 venous insufficiency 30.8 SELP PLAT F2 CRP
44 portal vein thrombosis 30.8 SELP MTHFR F2
45 coronary stenosis 30.8 PON1 CRP APOE APOB APOA1 ACE
46 marantic endocarditis 30.8 PLAT MTHFR F2
47 thrombophlebitis 30.8 PLAT MTHFR F2
48 supranuclear palsy, progressive, 1 30.8 APP APOE ACHE
49 inherited metabolic disorder 30.8 MTHFR CRP APOB APOA1
50 end stage renal failure 30.8 CRP APOB AGTR1 ACE

Comorbidity relations with Cerebrovascular Disease via Phenotypic Disease Network (PDN): (show all 37)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Anxiety
Aortic Valve Disease 1 Basilar Artery Insufficiency
Benign Essential Hypertension Bronchitis
Cerebral Atherosclerosis Cerebral Degeneration
Decubitus Ulcer Deficiency Anemia
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypertensive Encephalopathy
Hypothyroidism Intermediate Coronary Syndrome
Intracranial Embolism Intracranial Thrombosis
Iron Deficiency Anemia Labyrinthitis
Malignant Essential Hypertension Mitral Valve Disease
Osteoporosis Parkinson Disease, Late-Onset
Peripheral Vascular Disease Protein-Energy Malnutrition
Schizophreniform Disorder Sinoatrial Node Disease
Swallowing Disorders Transient Cerebral Ischemia
Vertebral Artery Insufficiency

Graphical network of the top 20 diseases related to Cerebrovascular Disease:



Diseases related to Cerebrovascular Disease

Symptoms & Phenotypes for Cerebrovascular Disease

UMLS symptoms related to Cerebrovascular Disease:


seizures, tremor, angina pectoris, edema, chest pain, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, equilibration disorder, sleeplessness, transient ischemic attacks, stereotypic symptoms

GenomeRNAi Phenotypes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.26 APOA1 APOB APOE SELP
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE SELP

MGI Mouse Phenotypes related to Cerebrovascular Disease:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 ACE ACHE AGTR1 APOA1 APOB APOE
2 cardiovascular system MP:0005385 10.37 ACE AGTR1 APOA1 APOB APOE APP
3 growth/size/body region MP:0005378 10.32 ACE ACHE AGTR1 APOB APOE APP
4 behavior/neurological MP:0005386 10.28 ACE ACHE AGTR1 APOE APP COL4A1
5 mortality/aging MP:0010768 10.25 ACE ACHE AGTR1 APOB APOE APP
6 hematopoietic system MP:0005397 10.24 ACE ACHE AGTR1 APOE APP COL4A1
7 immune system MP:0005387 10.23 ACE AGTR1 APOB APOE APP COL4A1
8 nervous system MP:0003631 10.1 ACHE AGTR1 APOB APOE APP COL4A1
9 integument MP:0010771 10.09 APOA1 APOE APP CX3CR1 F2 MTHFR
10 muscle MP:0005369 9.97 ACHE APOB APOE APP COL4A1 CX3CR1
11 reproductive system MP:0005389 9.9 ACE ACHE APOB APOE APP COL4A1
12 renal/urinary system MP:0005367 9.8 ACE AGTR1 APOE COL4A1 CX3CR1 NOTCH3
13 respiratory system MP:0005388 9.5 ACHE APOE COL4A1 F2 NOTCH3 PLAT
14 vision/eye MP:0005391 9.28 ACHE APOB APOE COL4A1 CX3CR1 MTHFR

Drugs & Therapeutics for Cerebrovascular Disease

Drugs for Cerebrovascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1181)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ticlopidine Approved Phase 4 55142-85-3 5472
2
Glyburide Approved Phase 4 10238-21-8 3488
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
5
Nadroparin Approved, Investigational Phase 4
6
Alogliptin Approved Phase 4 850649-61-5 11450633
7
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
8
Nicotine Approved Phase 4 54-11-5 942 89594
9
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
10
Galantamine Approved Phase 4 357-70-0 9651
11
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
12
Histamine Approved, Investigational Phase 4 51-45-6 774
13
Pantoprazole Approved Phase 4 102625-70-7 4679
14
Reteplase Approved, Investigational Phase 4 133652-38-7 65820
15
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
16
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
17
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
18
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
19
Bevacizumab Approved, Investigational Phase 4 216974-75-3
20
Zinc Approved, Investigational Phase 4 7440-66-6 32051
21
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
22
Phenindione Approved, Investigational Phase 4 83-12-5 4760
23
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
24
Ezetimibe Approved Phase 4 163222-33-1 150311
25
Enoxaparin Approved Phase 4 9005-49-6 772
26
Doxazosin Approved Phase 4 74191-85-8 3157
27
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
28
Manidipine Approved, Investigational Phase 4 89226-50-6
29
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
30
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
31
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
32
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
33
Edaravone Approved, Investigational Phase 4 89-25-8 70335
34
Tirofiban Approved Phase 4 144494-65-5 60947
35
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
36
Propafenone Approved Phase 4 54063-53-5 4932
37
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
38
Haloperidol Approved Phase 4 52-86-8 3559
39
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
40
Ziprasidone Approved Phase 4 146939-27-7 60854
41
Quinidine Approved, Investigational Phase 4 56-54-2 441074
42
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
43
Triflusal Approved, Investigational Phase 4 322-79-2
44
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
45
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
46
Insulin Aspart Approved Phase 4 116094-23-6 16132418
47
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
48
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
49
Tizanidine Approved, Investigational Phase 4 51322-75-9 5487
50
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622

Interventional clinical trials:

(show top 50) (show all 9188)
# Name Status NCT ID Phase Drugs
1 Study of Influence of Timing on Motor Learning Unknown status NCT02048826 Phase 4
2 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage Alzheimer's Disease Having Coexisting Small Vessel Cerebrovascular Disease Unknown status NCT02444637 Phase 4 Rivastigmine
3 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
4 The Impact of NBP on the Collateral Circulation in Acute Acute Internal Carotid Artery(ICA)/Middle Cerebral Artery(M1) Occlusion Unknown status NCT02594995 Phase 4 NBP
5 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
6 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
7 Efficacy of "Equistasi" on the Gait of Patients Affected by Hemiparesis Due to Cerebrovascular Accident Unknown status NCT02714478 Phase 4
8 Open-label Clinical Pharmacokinetic Study of Cardionat®, Capsules 250 mg (JSC Nizhpharm, Russia) Using in Health Athlete Volunteers Unknown status NCT02758912 Phase 4 оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
9 Effects of the Use of "de Novo" Everolimus for the Expression of Cytokines in Kidneys From Extended Criteria Donors and With Delayed Graft Function Unknown status NCT01663805 Phase 4 Everolimus
10 Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
11 Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients Unknown status NCT00567957 Phase 4 Remifentanil;Saline
12 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
13 Preventive Effects of Ginseng Against Atherosclerosis and Subsequent Ischemic Stroke: A Randomized Controlled Trial Unknown status NCT02796664 Phase 4
14 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
15 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue Unknown status NCT01554787 Phase 4 Chinese Herb Astragalus membranaceus
16 Phase IV Clinical Trial of Yiqitongluo Granule in the Treatment of Stroke With Qi-deficiency and Blood-stasis Syndrome Unknown status NCT02604654 Phase 4 Yiqitongluo granule
17 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
18 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
19 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
20 A Double Blind, Placebo Controlled Study to Evaluate the Efficacy of Melatonin in Acute Ischemic Stroke. Unknown status NCT01863277 Phase 4 Melatonin;placebo
21 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
22 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
23 Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Patients With Severe Motor Involvement at Subacute Phase of Stroke Unknown status NCT02768571 Phase 4 Cerebrolysin;Placebo
24 The Effectiveness of Ultrasound Guided Sub-acromial Bursa Injection With Botulinum Toxin A in for Refractory Shoulder Pain After Stroke. Unknown status NCT02618603 Phase 4 Botulinum toxin A;Triamcinolone Acetonide
25 Functional Electrical Stimulation (FES)-Assisted Walking: Enhancement of Voluntary Walking Function Among Persons With Severe Hemiplegia Post-Stroke Unknown status NCT00552916 Phase 4
26 Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction Unknown status NCT02386475 Phase 4 citalopram;sinemet plus
27 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
28 Nimodipine Preventing Cognitive Impairment in Ischemic Cerebrovascular Events: A Randomized, Placebo-Controlled, Double-Blind Trial (NICE) Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
29 Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke Unknown status NCT03252626 Phase 4 Alprostadil;Normal saline
30 Comparison Between Classical 4-point Canne and 4-roll Canne on Gait Parameters (Gait Speed and Energy Cost) as Walking Aids After Stroke. A Multicentric Randomized Controled Cross-over Study Unknown status NCT02279069 Phase 4
31 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
32 A Randomized Controlled Trial of Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
33 The THERAPY Trial: The Randomized, Concurrent Controlled Trial to Assess the Penumbra System's Safety and Effectiveness in the Treatment of Acute Stroke Unknown status NCT01429350 Phase 4 intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
34 Phase III Study of Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
35 A Phase IV, Double Blind, Placebo-controlled, Randomized, Multi-Center Study to Evaluate the Efficacy of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
36 Validation of Stroke Volume Variation and Pleth Variability Index as Predictors of Fluid Responsiveness in Patients Undergoing Robot Assisted Thyroidectomy Unknown status NCT02122367 Phase 4
37 The Hypertension in the Very Elderly Trial (HYVET) Unknown status NCT00122811 Phase 4 Indapamide SR 1.5mg; Perindopril 2-4mg
38 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
39 Prospective, Randomized, Open-label, Blinded Endpoints, Multi-center Study to Evaluate the Efficacy of Modest Blood Pressure Reduction With Diovan® (Valsartan) in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
40 Efficacy of Creative Therapy for Stroke Patients Unknown status NCT01455155 Phase 4
41 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
42 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
43 The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke Unknown status NCT02452502 Phase 4
44 The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack.10 vs 30 Days of Combination ASA and Clopidogrel Study Unknown status NCT02144831 Phase 4 anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
45 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
46 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
47 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
48 Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
49 Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
50 A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial Arterial Stenosis Unknown status NCT01553643 Phase 4 Chinese Herb Huang-Chi-Wu-Wu-Tang;placebo

Search NIH Clinical Center for Cerebrovascular Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Pentoxifylline
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Cochrane evidence based reviews: stroke

Genetic Tests for Cerebrovascular Disease

Anatomical Context for Cerebrovascular Disease

MalaCards organs/tissues related to Cerebrovascular Disease:

41
Brain, Heart, Testes, Endothelial, Kidney, Bone, Spinal Cord

Publications for Cerebrovascular Disease

Articles related to Cerebrovascular Disease:

(show top 50) (show all 44053)
# Title Authors PMID Year
1
Acetazolamide improves cerebral hemodynamics in CADASIL. 9 38
20227091 2010
2
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. 9 38
20485689 2010
3
The angiotensin II type 2 receptor in the brain. 9 38
19861353 2010
4
Lipids and carotid plaque in the Northern Manhattan Study (NOMAS). 9 38
20028534 2009
5
APOE-related mortality: effect of dementia, cardiovascular disease and gender. 9 38
18237822 2009
6
Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. 9 38
19200547 2009
7
Observation of the density and size of cells in hippocampus and vascular lesion in thalamus of GFAP-apoE transgenic mice. 9 38
19633698 2009
8
Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. 9 38
18985627 2009
9
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. 9 38
19417859 2009
10
CADASIL: extended polymorphisms and mutational analysis of the NOTCH3 gene. 9 38
19006080 2009
11
Report of two Chinese families and a review of Mainland Chinese CADASIL patients. 9 38
19167727 2009
12
Education attenuates the effect of medial temporal lobe atrophy on cognitive function in Alzheimer's disease: the MIRAGE study. 9 38
19542606 2009
13
MRI correlates of cognitive decline in CADASIL: a 7-year follow-up study. 9 38
19139365 2009
14
Age and apoE associations with complex pathologic features in Alzheimer's disease. 9 38
18653200 2008
15
Association of apolipoprotein E genotype and cerebrovascular disease risk factors in a Turkish population. 9 38
18576210 2008
16
Cystatin C expression in ischemic white matter lesions. 9 38
18261165 2008
17
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. 9 38
18548143 2008
18
Association of blood pressure and genetic background with white matter lesions in patients with mild cognitive impairment. 9 38
18511756 2008
19
PPAR-gamma Pro12Ala genotype and risk of cognitive decline in elders. 9 38
17052804 2008
20
New biochemical markers in acute coronary syndromes. 9 38
18537608 2008
21
Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. 9 38
17420019 2007
22
Polymorphisms of the renin-angiotensin system are associated with blood pressure, atherosclerosis and cerebral white matter pathology. 9 38
17220293 2007
23
Polymorphisms in apolipoprotein B and risk of ischemic stroke. 9 38
17595251 2007
24
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. 9 38
17534460 2007
25
Silent brain infarction and platelet activation in obstructive sleep apnea. 9 38
17341649 2007
26
Increased plasma levels of asymmetric dimethylarginine in patients with carotid stenosis: no evidence for the role of the common FABP2 A54T gene polymorphism. 9 38
17212611 2007
27
Delapril plus indapamide: a review of the combination in the treatment of hypertension. 9 38
17506588 2007
28
A perspective on telmisartan and cardiovascular risk. 9 38
17938615 2007
29
Amyloid beta-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. 9 38
17054909 2006
30
Cognitive impact of subcortical vascular and Alzheimer's disease pathology. 9 38
17192928 2006
31
Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population. 9 38
16945218 2006
32
Association of homocysteine (but not of MTHFR 677 C>T, MTR 2756 A>G, MTRR 66 A>G and TCN2 776 C>G) with ischaemic cerebrovascular disease in Sicily. 9 38
16894458 2006
33
Cognitive frailty: Predementia syndrome and vascular risk factors. 9 38
16023766 2006
34
Transient global amnesia in a patient with high and persistent levels of antiphospholipid antibodies. 9 38
16208431 2006
35
[The relationship between ApoE gene polymorphism and lipid parameters]. 9 38
16335008 2005
36
The spectrum of mutations for CADASIL diagnosis. 9 38
15995828 2005
37
Genetic variation of the intestinal fatty acid-binding protein 2 gene in carotid atherosclerosis. 9 38
16013194 2005
38
Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. 9 38
15681302 2005
39
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephaloapthy (CADASIL): a hereditary cerebrovascular disease, which can be diagnosed by skin biopsy electron microscopy. 9 38
15798438 2005
40
Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? 9 38
15662026 2005
41
T280M and V249I polymorphisms of fractalkine receptor CX3CR1 and ischemic cerebrovascular disease. 9 38
15644279 2005
42
[Mutations of genes associated with thromboses in ischemic stroke in patients with primary antiphospholipid syndrome]. 9 38
16320685 2005
43
Carotid artery intima-media thickness and angiotensin-converting enzyme gene polymorphism in the offspring of parents with premature stroke. 9 38
15858957 2005
44
The FABP2 gene polymorphism in cerebrovascular disease. 9 38
15527447 2004
45
ACE genotype and cognitive decline in an African-Caribbean population. 9 38
15465635 2004
46
123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. 9 38
15471834 2004
47
Plasma adrenomedullin and carotid atherosclerosis in atherothrombotic ischemic stroke. 9 38
15361766 2004
48
Vascular injury in systemic sclerosis: angiotensin-converting enzyme insertion/deletion polymorphism. 9 38
15016346 2004
49
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. 9 38
15161326 2004
50
Apolipoprotein E genotype and subcortical vascular lesions in older depressed patients and control subjects. 9 38
14512206 2003

Variations for Cerebrovascular Disease

Expression for Cerebrovascular Disease

Search GEO for disease gene expression data for Cerebrovascular Disease.

Pathways for Cerebrovascular Disease

Pathways related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 SERPINA3 SELP PLAT F2 APP APOB
2
Show member pathways
12.41 MTR MTHFR APOE APOB APOA1
3
Show member pathways
11.65 PLAT F2 CX3CR1 COL4A1 APP
4
Show member pathways
11.64 COL4A1 APOE APOB APOA1
5
Show member pathways
11.61 SERPINA3 PLAT MTR MTHFR F2 CRP
6 11.23 SELP PLAT APOB
7 10.79 PLAT APP ACE
8 10.76 CX3CR1 APP APOE ACE
9 10.54 MEG3 HOTAIR

GO Terms for Cerebrovascular Disease

Cellular components related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 collagen-containing extracellular matrix GO:0062023 9.89 SERPINA3 PLAT COL4A1 APOE APOA1
2 early endosome GO:0005769 9.85 APP APOE APOB APOA1
3 extracellular region GO:0005576 9.77 SERPINA3 PON1 PLAT NOTCH3 F2 CRP
4 endoplasmic reticulum lumen GO:0005788 9.73 F2 COL4A1 APP APOE APOB APOA1
5 blood microparticle GO:0072562 9.72 SERPINA3 PON1 F2 APOE APOA1
6 high-density lipoprotein particle GO:0034364 9.65 PON1 APOE APOA1
7 very-low-density lipoprotein particle GO:0034361 9.63 APOE APOB APOA1
8 endocytic vesicle lumen GO:0071682 9.61 APOE APOB APOA1
9 low-density lipoprotein particle GO:0034362 9.58 APOE APOB APOA1
10 synaptic cleft GO:0043083 9.56 APOE ACHE
11 spherical high-density lipoprotein particle GO:0034366 9.54 PON1 APOA1
12 chylomicron GO:0042627 9.54 APOE APOB APOA1
13 discoidal high-density lipoprotein particle GO:0034365 9.51 APOE APOA1
14 extracellular space GO:0005615 9.44 SERPINA3 SELP PON1 PLAT F2 CRP
15 intermediate-density lipoprotein particle GO:0034363 9.33 APOE APOB APOA1
16 extracellular exosome GO:0070062 10.18 SERPINA3 PON1 PLAT F2 APP APOE

Biological processes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 cholesterol homeostasis GO:0042632 9.83 APOE APOB APOA1
2 platelet degranulation GO:0002576 9.83 SERPINA3 SELP APP APOA1
3 cellular protein metabolic process GO:0044267 9.83 F2 APP APOE APOB APOA1
4 response to wounding GO:0009611 9.8 F2 CX3CR1 ACHE
5 retinoid metabolic process GO:0001523 9.76 APOE APOB APOA1
6 acute-phase response GO:0006953 9.72 SERPINA3 F2 CRP
7 triglyceride catabolic process GO:0019433 9.69 APOE APOB APOA1
8 lipoprotein metabolic process GO:0042157 9.67 APOE APOB APOA1
9 positive regulation of cholesterol efflux GO:0010875 9.66 PON1 APOE
10 regulation of blood vessel diameter GO:0097746 9.65 AGTR1 ACE
11 high-density lipoprotein particle assembly GO:0034380 9.65 APOE APOA1
12 cholesterol efflux GO:0033344 9.65 APOE APOB APOA1
13 phospholipid efflux GO:0033700 9.64 APOE APOA1
14 methionine biosynthetic process GO:0009086 9.64 MTR MTHFR
15 amyloid precursor protein metabolic process GO:0042982 9.63 APOE ACHE
16 high-density lipoprotein particle clearance GO:0034384 9.63 APOE APOA1
17 artery morphogenesis GO:0048844 9.63 NOTCH3 APOE APOB
18 very-low-density lipoprotein particle remodeling GO:0034372 9.62 APOE APOA1
19 negative regulation of platelet activation GO:0010544 9.61 F2 APOE
20 chylomicron remnant clearance GO:0034382 9.61 APOE APOB
21 regulation of cholesterol transport GO:0032374 9.6 APOE APOA1
22 regulation of Cdc42 protein signal transduction GO:0032489 9.59 APOE APOA1
23 very-low-density lipoprotein particle clearance GO:0034447 9.58 APOE APOB
24 low-density lipoprotein particle remodeling GO:0034374 9.58 APOE APOB AGTR1
25 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.57 AGTR1 ACE
26 positive regulation of amyloid fibril formation GO:1905908 9.56 APP APOE
27 lipoprotein catabolic process GO:0042159 9.54 APOE APOB
28 negative regulation of long-term synaptic potentiation GO:1900272 9.54 CX3CR1 APP APOE
29 chylomicron assembly GO:0034378 9.5 APOE APOB APOA1
30 positive regulation of cholesterol esterification GO:0010873 9.43 APOE APOA1 AGTR1
31 chylomicron remodeling GO:0034371 9.33 APOE APOB APOA1
32 lipoprotein biosynthetic process GO:0042158 9.13 APOE APOB APOA1
33 cholesterol metabolic process GO:0008203 9.02 PON1 APP APOE APOB APOA1

Molecular functions related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 amyloid-beta binding GO:0001540 9.63 APOE APOA1 ACHE
2 phospholipid binding GO:0005543 9.62 PON1 APOE APOB APOA1
3 lipid transporter activity GO:0005319 9.54 APOE APOB APOA1
4 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.43 APOE APOA1
5 lipoprotein particle binding GO:0071813 9.4 APOE APOA1
6 low-density lipoprotein particle receptor binding GO:0050750 9.33 CRP APOE APOB
7 bradykinin receptor binding GO:0031711 9.26 AGTR1 ACE
8 cholesterol transporter activity GO:0017127 9.13 APOE APOB APOA1
9 heparin binding GO:0008201 9.02 SELP F2 APP APOE APOB

Sources for Cerebrovascular Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
61